Aging and Olmesartan

Summary of research on aging and OlmesartanMedication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. Also known by the trade name Benicar. taken from article Science behind olmesartan

Benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. ¹⁾

In conclusion, there is no robust signal for harm with olmesartan use. ²⁾

Although uncontrolled confounding might still exist, olmesartan does not seem to increase cardiovascular risk compared with losartan. ³⁾

include the ability to:

• decrease the incidence and progression of Alzheimer's disease and dementia⁴⁾
• prevent migraines⁵⁾
• inhibit liver fibrosis and aid liver healing⁶⁾
• reduce insulin resistance in rats⁷⁾
• 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats⁸⁾
• protect the mitochondria from age-associated damage from oxidation⁹⁾
• play a protective role against proliferative diabetic retinopathy ¹⁰⁾
• reduce liver fibrosis¹¹⁾
• treatment of anxiety and stress-related disorders¹²⁾
• reduce oxidative damage¹³⁾ and limit aging ^{14) 15)}

to block various bad effects of Angiotensin II, including heart failure. In this regard, olmesartan has been shown to:

• protect the heart from damage from inflammationThe complex biological response of vascular tissues to harmful stimuli such as pathogens or damaged cells. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. in myocarditis¹⁶⁾
• ameliorate acute experimental autoimmuneA condition or disease thought to arise from an overactive immune response of the body against substances and tissues normally present in the body myocarditis, in rats, suppressing cytotoxic myocardial injury ¹⁷⁾
• prevent acute left ventricular dysfunction¹⁸⁾
• lower C-reactive protein, one of the acute phase proteins that increase during systemic inflammation¹⁹⁾
• act as an antiarrhythmic²⁰⁾
• block the production of Angiotensin II, thus improving mortality rates in heart failure patients²¹⁾
• This study demonstrated that olmesartan reduced angiotensin II and aldosterone levels more effectively than azilsartan, resulting in a stable antihypertensive effect. Olmesartan also had an inhibitory effect on cardiac hypertrophy. Accordingly, it may be effective for patients with increased RAAS activity after cardiac surgery or patients with severe cardiac hypertrophy. ²²⁾
• Conclusion: In the present study, left ventricular hypertrophy and on arterial compliance were inhibited by a decrease in angiotensin II and aldosterone due to the change-over to olmesartan. In the future, protective effects on organs will be clarified by long-term observations. ^{23) 24)}

80mg single dose vs 6hrlydosing

4 hourly compared to 6 hourly dosing

In August 2002, Trevor Marshall and Frances Marshall published a NetPrint about valsartan (Diovan), in which they reported that the once daily dosing of the ARBA drug which is an angiotensin receptor blocker. One of the ARBs is olmesartan (Benicar). Not all ARBs activate the Vitamin D Receptor. caused psychedelic dreams and psychotic events in two sarcoidosis patients. On the theory that these symptoms were caused by changes in plasma concentration, the frequency of the dosing of ARB was increased, which ended up reducing symptoms of disease including psychedelic dreams. This early insight into ARBs anti-inflammatory effects led Marshall to conclude that for an ARB to provide symptomatic relief, it was necessary to use more frequent dosing than typical. Professor Marshall would later go on to recommend frequent dosing of another ARB, olmesartan.

In rats, Olmesartan at 6 mg/kg optimally reduced the inflammatory process and bone loss²⁵⁾. That would be 9-10 tablets of Olmetec daily for a 64 Kg human

• prevent or delay left ventricular remodeling and hypertrophy in patients with type 2 diabetes ²⁶⁾
• reduce the volume of atherosclerotic plaques^{27) 28)}
• mildly reduce the risk of stroke in people at high risk for strokes (cerebrovascular events).²⁹⁾
• significantly remodel and destiffen the arterial wall material during long-term treatment ³⁰⁾

that olmesartan and other ARBs possess various ways of protecting the kidneys from the effects of inflammation and cytokineAny of various protein molecules secreted by cells of the immune system that serve to regulate the immune system. damage:

• in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization ³¹⁾
• in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition ³²⁾
• results suggest olmesartan can help decrease plasma AGE levels in patients on HD ³³⁾
• renal protective effects of olmesartan may be better than those of other ARBs ³⁴⁾
• olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects ³⁵⁾

• treatment with olmesartan inhibited bone loss ³⁶⁾
• olmesartan protects endothelial cells against oxidative stress-mediated cellular injury ³⁷⁾
• decreases viability of malignant cell lines³⁸⁾
• carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques ³⁹⁾
• improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan ⁴⁰⁾
• improvement of glycemic control & insulin resistance was only observed in olmesartan group ⁴¹⁾
• OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes ⁴²⁾
• prevention of microalbuminuria in patients with type 2 diabetes and hypertension ⁴³⁾

Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint ⁴⁴⁾